Sandoz is the generic pharmaceutical division of Novartis and a world leader in the generics industry, whose roots date back more than 120 years with decades of biotechnology know-how. We develop, produce and market a portfolio of approximately 1 100 high-quality and cost-effective generic compounds, including complex biosimilars, an emerging field in which we are the pioneer and global leader. Sandoz also leads the way in the development and production of differentiated, value-added generics that make a real difference in peoples’ lives, furthering the world’s access to affordable, high-quality healthcare.
For more information about Sandoz, please review our web pages. All additional investor information can be found on Novartis’ Investor pages: